CN111500731A - Kit for early diagnosis, detection or screening of thyroid cancer, and use method and application thereof - Google Patents

Kit for early diagnosis, detection or screening of thyroid cancer, and use method and application thereof Download PDF

Info

Publication number
CN111500731A
CN111500731A CN202010429151.4A CN202010429151A CN111500731A CN 111500731 A CN111500731 A CN 111500731A CN 202010429151 A CN202010429151 A CN 202010429151A CN 111500731 A CN111500731 A CN 111500731A
Authority
CN
China
Prior art keywords
dna
kit
methylation
probes
specific
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN202010429151.4A
Other languages
Chinese (zh)
Inventor
王志强
万季
蔡雪儿
罗海燕
王一杏
夏迪
汪健
金泰庆
关建洪
王弈
宋麒
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Shenzhen Neocura Biotechnology Corp
Original Assignee
Shenzhen Neocura Biotechnology Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Shenzhen Neocura Biotechnology Corp filed Critical Shenzhen Neocura Biotechnology Corp
Priority to CN202010429151.4A priority Critical patent/CN111500731A/en
Publication of CN111500731A publication Critical patent/CN111500731A/en
Pending legal-status Critical Current

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • C12Q1/6886—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6844—Nucleic acid amplification reactions
    • C12Q1/6858—Allele-specific amplification
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/154—Methylation markers

Landscapes

  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Engineering & Computer Science (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Immunology (AREA)
  • Analytical Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Biotechnology (AREA)
  • Microbiology (AREA)
  • Molecular Biology (AREA)
  • General Health & Medical Sciences (AREA)
  • General Engineering & Computer Science (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Oncology (AREA)
  • Hospice & Palliative Care (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)

Abstract

The invention discloses a kit for early diagnosis, detection or screening of thyroid cancer, and a use method and application thereof. The kit comprises specific primers and probes for detecting or measuring the methylation state or level of one or more specific genes in the DNA of a test sample, wherein the specific genes are BNC1 and ACTB. The kit can obviously improve the positive detection rate and specificity (real negative rate) of early thyroid cancer, can improve the detection sensitivity of the biomarker to DNA molecules of picogram/nanogram grade, and is realized by optimizing specific nucleotide sequence primers and DNA probes and improving a bisulfite treatment method of plasma free DNA.

Description

Kit for early diagnosis, detection or screening of thyroid cancer, and use method and application thereof
Technical Field
The invention belongs to the technical field of biotechnology and DNA detection, and particularly relates to a DNA methylation qPCR kit for thyroid cancer detection, and a using method and application thereof, in particular to a kit for determining the methylation state of a target gene target (such as BNC1 and NR2F1) by using plasma free DNA for thyroid cancer detection or screening, and a using method thereof, and further relates to application of the detection kit in biomedicine.
Background
The incidence of thyroid cancer is the first of endocrine tumors and is one of the most common malignant tumors of the head and neck. The latest national cancer report in 2018 indicates that thyroid cancer mainly appears in female population, the incidence of thyroid cancer of female in developed countries ranks 7 th, and the incidence of thyroid cancer of female in developing countries ranks 9 th. The incidence rate of thyroid cancer in eastern areas of China is far higher than that in middle and western areas, and the incidence rate of female is far higher than that of male. Thyroid cancer is the most prominent type of cancer in the female population under the age of 30. In recent years, the incidence rate of thyroid cancer in China is obviously increased, but the death rate is relatively stable at a lower level, and other countries also find similar trends, which may be related to over-diagnosis of thyroid cancer. The incidence rate of thyroid cancer in China is different in regions, which is probably caused by different screening rates of thyroid cancer in different regions.
Thyroid nodules refer to sporadic lesions caused by local abnormal growth of thyroid cells. Cervical ultrasound is the primary method of examination for initial cancer risk stratification of thyroid nodules, followed by a decision as to whether to take a Fine Needle Aspiration Biopsy (FNAB) of a suspicious nodule. However, in some cases, it is difficult for about 20% to 40% of preoperative biopsies to distinguish benign thyroid nodules from thyroid cancer due to the cytological feature overlap between malignant and benign thyroid nodules. In addition, laboratory serological examinations (thyroid stimulating hormone (TSH), thyroglobulin (Tg) and calcitonin (Ct)) are also currently common methods for clinically identifying benign and malignant nodules, but are less specific due to their higher content in thyroid non-tumor diseases. Reports indicate that uncertainty in TC diagnosis results in up to 50,000 patients receiving unnecessary thyroidectomies each year in the united states alone. Therefore, the supplement and perfection of the conventional TC patient diagnosis method remains a problem to be solved urgently.
ctDNA (circulating tumor DNA) released by tumor cell necrosis and apoptosis can be detected in peripheral blood of tumor patients, and due to the fact that ctDNA methylation is carried with molecular genetic changes consistent with primary tumor tissues, tumors can be diagnosed theoretically by using ctDNA methylation.
Disclosure of Invention
Based on the above data, we have found better methylated gene targets for early thyroid cancer screening through more extensive and intensive research, and have designed several sets of primer and probe combinations for methylation detection of these targets, and have made the detection and screening of early thyroid cancer and the kit for identifying benign and malignant thyroid nodules by using the newly found gene target detection combinations.
The invention aims to provide a blood monogene detection primer probe combination kit for early diagnosis, detection or screening of thyroid cancer, which aims to overcome the defects of low specificity and sensitivity of a detection method in the prior art.
The first aspect of the invention provides a kit for early diagnosis, detection or screening of thyroid cancer, which comprises specific primers and probes for detecting or measuring the methylation state or level of one or more specific genes in DNA of a test sample, wherein the specific genes are BNC1 and ACTB.
In some embodiments, the specific primers and probes used to detect or measure the methylation state or level of the BNC1 gene in the test sample DNA are selected from any one of the following three specific primer and probe combinations: 1-2 specific primers and 3 probes, 4-5 specific primers and 6 probes, 7-8 specific primers and 9 probes.
In some embodiments, the specific primers used to detect or measure the methylation state or level of the ACTB gene in the test sample DNA are specific primers SEQ ID NO 10-11 and probe SEQ ID NO 12.
In some embodiments, the SEQ ID NOs 1, 2, 4, 5, 7, 8, 10, 11 are all phosphorothioate modified and hybridize under stringent conditions to a region of the target gene that is either methylated or unmethylated.
In some embodiments, the SEQ ID NOs 3, 6, 9, 12 are designed based on TaqMan and hybridize under stringent conditions to a region of a target gene, which is methylated or unmethylated.
In some embodiments, the nucleotide sequences of SEQ ID NO 3, 6, 9 are labeled FAM at the 5 'end and QSY at the 3' end.
In some embodiments, the nucleotide sequence of SEQ ID NO 12 is labeled 5 'with VIC and 3' with MGBNFQ.
In some embodiments, the specific primers SEQ ID NO. 1, 2, 4, 5, 7, 8, 10, 11 and the probes SEQ ID NO. 3, 6, 9, 12 are 10-50nt in length.
In some embodiments, the kit further comprises the following components: dNTP mixed solution, MgCl2 solution, DNA polymerase, PCR reaction buffer solution and PCR deionized water.
In some embodiments, the kit further comprises the following components: a plasma free DNA extraction reagent and a plasma free DNA methylation conversion reagent.
In some embodiments, the plasma free DNA methylation conversion reagent is bisulfite.
In some embodiments, the test sample DNA is whole genome, cell-free DNA, or circulating tumor DNA.
In some embodiments, specific primer and probe sequences are shown in table 1 below:
TABLE 1 specific primers and probes contained in the kit of the invention
Figure BDA0002499853770000031
A second aspect of the invention provides a method of using a kit according to the first aspect, comprising the steps of:
(1) extracting plasma free DNA;
(2) performing methylation conversion on the extracted plasma free DNA and purifying, wherein bisulfite is preferably used as a reagent for performing methylation conversion on the plasma free DNA;
(3) carrying out fluorescent quantitative PCR amplification on the free DNA of the plasma subjected to methylation conversion and purification, setting a Ct threshold value in a linear amplification interval after the PCR reaction is finished, and determining that the amplification with the Ct value less than 40 is positive;
(4) and (4) judging a result: when the detection result of the internal reference site ACTB is positive, determining that the result of the target point is positive if at least two of the three repeated amplifications of the BNC1 target point are positive;
preferably, in the step (3), PCR amplification of each template is performed in three repetitions.
In some embodiments, each reaction system is 10 μ L, which contains (0.5-1.5 μ L) 1xPCR reaction buffer, 200-.
In some embodiments, the primers for the target of the BNC1 gene region are each 300-500 nM.
In some embodiments, the BNC1 gene region targets 200-300nM each.
In some embodiments, the primer for the target of the ACTB gene region is 150-250nM and the probe for the target of the ACTB gene region is 50-150 nM.
In some embodiments, the PCR amplification conditions are: pre-denaturation at 90-100 deg.C for 8-12 min; denaturation at 90-100 deg.C for 10-20s, annealing at 60-70 deg.C and extension for 60-70s, and 40-50 cycles.
In some embodiments, the step (3) is performed by any one of the following methods: methylation specific quantitative PCR, real-time methylation specific PCR, PCR using methylated DNA specific binding proteins.
The third aspect of the invention provides the medical use of the kit according to the first aspect in preparing a reagent or medical device for early diagnosis, detection or screening of thyroid cancer.
The invention has the beneficial effects that:
the kit can obviously improve the positive detection rate and specificity (real negative rate) of early thyroid cancer, can improve the detection sensitivity of the biomarker to DNA molecules of picogram/nanogram grade, and is realized by optimizing specific nucleotide sequence primers and DNA probes and improving a bisulfite treatment method of plasma free DNA.
Drawings
FIG. 1 is a graph of a methylated qPCR amplification plot of a blood sample of a healthy person from a kit according to one embodiment of the invention;
FIG. 2 is a diagram of a thyroid cancer methylation qPCR amplification curve of a thyroid cancer patient blood sample of a kit according to an embodiment of the present invention.
Detailed Description
The embodiments of the present invention are described below with reference to specific embodiments, and other advantages and effects of the present invention will be easily understood by those skilled in the art from the disclosure of the present specification. The invention is capable of other and different embodiments and of being practiced or of being carried out in various ways, and its several details are capable of modification in various respects, all without departing from the spirit and scope of the present invention.
Before the present embodiments are further described, it is to be understood that the scope of the invention is not limited to the particular embodiments described below; it is also to be understood that the terminology used in the examples is for the purpose of describing particular embodiments only, and is not intended to limit the scope of the present invention.
Materials, reagents and the like used in the following examples are commercially available unless otherwise specified.
Definition of
The terms "patient," "individual," or "subject" are used interchangeably herein and may refer to a mammal, particularly a human. The subject may have mild, moderate or severe disease. The patient may be untreated, susceptible to treatment, or refractory. The patient may be an individual in need of treatment or diagnosis based on a particular symptom or family history.
The terms "sample," "patient sample," "biological sample," and the like include various sample types obtained from a patient, individual, or subject, and can be used for diagnostic or monitoring assays. The patient sample can be obtained from a healthy subject, a diseased patient, or a patient with thyroid cancer-related symptoms. Furthermore, the sample obtained from the patient may be segmented and only a portion may be used for diagnosis. In addition, the sample or a portion thereof may be stored under conditions that maintain the sample for later analysis. Specifically included within this definition are blood and other liquid samples of biological origin (including but not limited to peripheral blood, serum, plasma, urine, saliva, sputum, stool, and synovial fluid), solid tissue samples (such as biopsy specimens or tissue cultures or cells derived therefrom and progeny thereof). The definition also includes samples that are manipulated in any manner after being obtained, such as by centrifugation, filtration, precipitation, dialysis, chromatography, reagent treatment, washing, or enrichment for certain cell populations. These terms also include clinical samples, cultured cells, cell supernatants, tissue samples, organs, and the like. The sample may also comprise freshly frozen and/or formalin fixed paraffin embedded tissue blocks, such as blocks prepared by clinical or pathological biopsy, prepared for pathological analysis or by immunohistochemistry studies.
The terms "measuring," "determining," "detecting," or "examining" are used interchangeably throughout and may refer to a method that includes obtaining a patient sample and/or detecting a biomarker methylation status or level in a patient sample. In one embodiment, these terms refer to obtaining a patient sample and detecting the methylation state or level of one or more biomarkers in the sample. In another embodiment, the terms "measuring", "determining" or "detecting" refer to detecting the methylation status or level of one or more biomarkers in a patient sample. Measurement can be accomplished by methods known in the art and further described herein, including but not limited to methylation specific quantitative polymerase chain reaction (qPCR).
The term "methylation" refers to methylation of cytosine at the C5 or N4 position of cytosine, the N6 position of adenine, or other types of nucleic acid methylation. The in vitro amplified DNA is unmethylated because the in vitro DNA amplification method does not preserve the methylation pattern of the amplified template. However, "unmethylated DNA" or "methylated DNA" can also refer to amplified DNA whose original template was unmethylated or methylated, respectively.
The term "CpG island" refers to a contiguous region of genomic DNA having a high density of CpG.
The term "methylation state" or "methylation level" refers to the presence, absence, and/or amount of methylation at a particular nucleotide or nucleotide in a portion of DNA.
It should be understood that wherever the language "comprising" is used to describe an embodiment, other similar embodiments described in "consisting of …" and/or "consisting essentially of …" are also provided.
Example 1: method for carrying out thyroid cancer methylation qPCR (quantitative polymerase chain reaction) detection on healthy human cfDNA (cfDNA) sample by using kit
(I) test materials
1.5 parts of healthy human plasma;
QIAamp circulatory system nucleic acid extraction kit (purchased from Qiagen, Inc.);
EZ DNA Methylation-L lightening kit (available from Zymo Research Co.);
4. the kit (comprises a combination 1 primer and probe combination for detecting a target point BNC1, and an ACTB amplification primer and probe);
5.AmpliTaq GoldTMDNA polymerase and buffer reagents (available from Thermo Fisher).
(II) Experimental method
1. Plasma free DNA extraction
cfDNA was extracted from 5 healthy human plasma samples using QIAamp circulatory system nucleic acid extraction kit, the procedure was performed according to the kit instructions.
2. Free DNA methylation conversion
Extracted 5 plasma cfDNA was bisulfite-treated and then purified using EZ DNA Methylation-L lightening kit from Zymo Research.
qPCR amplification
The bisulfite treated plasma cfDNA was subjected to qPCR amplification using a Thermo Fisher Quant Studio 5 instrument with three replicates of PCR amplification per template 10. mu. L for each reaction system containing 1xPCR reaction buffer, 400. mu.m dNTPs, 4mM MgCl22U AmpliTaq Gold DNA polymerase; 800nM each of the primers for the target of the BNC1 gene region (only one pair of primers was selected for each target), 500nM each of the probes for the target of the BNC1 gene region (one probe was selected for each target corresponding to the primer selected); primer 200nM of ACTB gene region target, probe 100nM of ACTB gene region target; 50nM ROX dye.
The PCR amplification conditions were: pre-denaturation at 95 ℃ for 10 min;
denaturation at 95 ℃ for 15s, annealing and extension at 65 ℃ for 30s, 45 cycles;
after the PCR reaction was completed, the Ct threshold was set in the linear amplification region (in this experiment,. DELTA.Rn was set to 0.1), and amplification with a Ct value of less than 40 was considered positive.
(III) results of the experiment
The criteria for the result is that when the internal reference site (ACTB) test is positive, at least two of the three duplicate amplifications at the test site/target of BNC1 are positive and the sample is determined to be positive.
Table 2 below shows the results of 5 healthy human plasma samples determined using the present invention (fig. 1). As can be seen from Table 2, the detection specificity of this protocol is very high.
TABLE 2 results of the detection of blood samples of healthy persons using the kit of the present invention
Figure BDA0002499853770000071
Example 2: the kit is used for carrying out thyroid cancer methylation qPCR detection on ctDNA samples of thyroid cancer patients
(I) test materials
1.5 parts of thyroid cancer patient plasma;
QIAamp circulatory system nucleic acid extraction kit (purchased from Qiagen, Inc.);
EZ DNA Methylation-L lightening kit (available from Zymo Research Co.);
4. the kit (comprises a combination 1 primer and probe combination for detecting a target point BNC1, and an ACTB amplification primer and probe);
5.AmpliTaq GoldTMDNA polymerase and buffer reagents (available from Thermo Fisher).
(II) Experimental method
1. Plasma free DNA extraction
ctDNA was extracted from 5 thyroid cancer patient plasma samples using QIAamp circulatory system nucleic acid extraction kit, and the procedure was performed according to the kit instructions.
2. Free DNA methylation conversion
Extracted 5 plasma ctDNA was bisulfite-treated and then purified using EZ DNA Methylation-L lightening kit from Zymo Research.
qPCR amplification
The bisulfite treated plasma ctDNA was subjected to qPCR amplification using a Thermo Fisher Quant Studio 5 instrument with three replicates of PCR amplification for each template 10. mu. L each containing 1xPCR reaction buffer, 400. mu.m dNTPs, 4mM MgCl22U AmpliTaq Gold DNA polymerase; 800nM each of the primers for the target of the BNC1 gene region (only one pair of primers was selected for each target), 500nM each of the probes for the target of the BNC1 gene region (one probe was selected for each target corresponding to the primer selected); primer 200nM of ACTB gene region target, probe 100nM of ACTB gene region target; 50nM ROX dye.
The PCR amplification conditions were: pre-denaturation at 95 ℃ for 10 min;
denaturation at 95 ℃ for 15s, annealing and extension at 65 ℃ for 30s, 45 cycles;
after the PCR reaction was completed, the Ct threshold was set in the linear amplification region (in this experiment,. DELTA.Rn was set to 0.1), and amplification with a Ct value of less than 40 was considered positive.
(III) results of the experiment
The criteria for the result is that when the internal reference site (ACTB) test is positive, at least two of the three duplicate amplifications at the test site/target of BNC1 are positive and the sample is determined to be positive.
Table 3 below shows the results of plasma samples of 5 thyroid cancer patients measured using the present invention (fig. 2). As can be seen from Table 3, the positive detection rate of this protocol was very high.
TABLE 3 test results of thyroid cancer patients blood samples using the kit of the present invention
Figure BDA0002499853770000081
By combining the example 1 and the example 2, it can be seen that the kit of the present invention for thyroid cancer screening has a positive detection rate of 100%, a specificity (true negative rate) of 100%, and an area under the curve of 1.0.
Different from example 2, the combination of primer and probe 2 comprising the target detection BNC1 and the combination of primer and probe 2 comprising the target detection BNC1 all obtained results equivalent to example 2 in the blood samples of 9 patients with thyroid cancer, and the positive detection rate was 100%.
While the preferred embodiments and examples of the present invention have been described in detail, the present invention is not limited to the embodiments and examples, and various changes can be made without departing from the spirit of the present invention within the knowledge of those skilled in the art.
Sequence listing
<110> Shenzhen Xinhe biomedical science and technology Limited
<120> thyroid cancer early diagnosis, detection or screening kit, and use method and application thereof
<160>12
<170>SIPOSequenceListing 1.0
<210>1
<211>18
<212>DNA
<213> Artificial sequence ()
<400>1
tcgtggaaac gtagattc 18
<210>2
<211>21
<212>DNA
<213> Artificial sequence ()
<400>2
cgaaaatcgc gaatattccg c 21
<210>3
<211>18
<212>DNA
<213> Artificial sequence ()
<400>3
gtttaatttt agagatta 18
<210>4
<211>20
<212>DNA
<213> Artificial sequence ()
<400>4
cgggttagaa ggtaggaggc 20
<210>5
<211>21
<212>DNA
<213> Artificial sequence ()
<400>5
aaaaacgatt actttcgccc g 21
<210>6
<211>18
<212>DNA
<213> Artificial sequence ()
<400>6
cggtggcggg cgaaagta 18
<210>7
<211>21
<212>DNA
<213> Artificial sequence ()
<400>7
tcgggttaga aggtaggagg c 21
<210>8
<211>22
<212>DNA
<213> Artificial sequence ()
<400>8
atcgaatcta cgtttccacg aa 22
<210>9
<211>20
<212>DNA
<213> Artificial sequence ()
<400>9
gattactttc gcccgccacc 20
<210>10
<211>26
<212>DNA
<213> Artificial sequence ()
<400>10
tagggagtat ataggttggg gaagtt 26
<210>11
<211>27
<212>DNA
<213> Artificial sequence ()
<400>11
aacacacaat aacaaacaca aattcac 27
<210>12
<211>25
<212>DNA
<213> Artificial sequence ()
<400>12
tggtgatgga ggaggtttag gcagt 25

Claims (10)

1. A kit for early diagnosis, detection or screening of thyroid cancer comprises specific primers and probes for detecting or measuring the methylation state or level of one or more specific genes in DNA of a test sample, wherein the specific genes are BNC1 and ACTB.
2. The kit of claim 1, wherein the specific primers and probes for detecting or measuring the methylation state or level of BNC1 gene in the test sample DNA are selected from any one of the following three specific primer and probe combinations: 1-2 specific primers and 3 probes, 4-5 specific primers and 6 probes, 7-8 specific primers and 9 probes.
3. The kit according to claim 1 or 2, wherein the specific primers for detecting or measuring the methylation state or level of the ACTB gene in the test sample DNA are specific primers SEQ ID NOs 10 to 11 and probe SEQ ID NO 12.
4. The kit of any one of claims 1 to 3, wherein each of SEQ ID NOs 1, 2, 4, 5, 7, 8, 10, 11 is modified with phosphorothioate and hybridizes under stringent conditions to a region of a target gene that is methylated or unmethylated;
and/or said SEQ ID NO 3, 6, 9, 12 are designed on the basis of TaqMan (TM) and hybridize under stringent conditions to a methylated or unmethylated target gene region.
5. The kit according to any one of claims 1 to 4, wherein the nucleotide sequences of SEQ ID NO 3, 6, 9 are labeled with FAM at the 5 'end and QSY at the 3' end;
and/or the nucleotide sequence of SEQ ID NO 12 is marked with VIC at the 5 'end and MGBNFQ at the 3' end.
6. The kit according to any one of claims 1 to 5, wherein the specific primers SEQ ID NO 1, 2, 4, 5, 7, 8, 10, 11 and the probes SEQ ID NO 3, 6, 9, 12 are 10 to 50nt in length.
7. The kit according to any one of claims 1 to 6, further comprising the following components: dNTP mixed solution, MgCl2 solution, DNA polymerase, PCR reaction buffer solution and PCR deionized water;
and/or, the kit also comprises the following components: a plasma free DNA extraction reagent and a plasma free DNA methylation conversion reagent;
and/or, the plasma free DNA methylation conversion reagent is bisulfite;
and/or, the test sample DNA is whole genome, cell-free DNA, or circulating tumor DNA.
8. A method of using the kit according to any one of claims 1 to 7, comprising the steps of:
(1) extracting plasma free DNA;
(2) performing methylation conversion on the extracted plasma free DNA and purifying, wherein bisulfite is preferably used as a reagent for performing methylation conversion on the plasma free DNA;
(3) carrying out fluorescent quantitative PCR amplification on the free DNA of the plasma subjected to methylation conversion and purification, setting a Ct threshold value in a linear amplification interval after the PCR reaction is finished, and determining that the amplification with the Ct value less than 40 is positive;
(4) and (4) judging a result: when the detection result of the internal reference site ACTB is positive, determining that the result of the target point is positive if at least two of the three repeated amplifications of the BNC1 target point are positive;
preferably, in the step (3), the PCR amplification of each template is performed in three repetitions;
and/or, each reaction system is 10 mu L, which contains (0.5-1.5 mu L) 1xPCR reaction buffer, 200-400 mu m dNTPs, 3-6mM MgCl2, 1-3U AmpliTaq Gold DNA polymerase;
and/or, the primer of the BNC1 gene region target point is respectively 300-500 nM;
and/or, the probes for the BNC1 gene region target point are respectively 200-300 nM;
and/or, primer 150-250nM of ACTB gene region target, probe 50-150nM of ACTB gene region target;
and/or, the PCR amplification conditions are as follows: pre-denaturation at 90-100 deg.C for 8-12 min; denaturation at 90-100 deg.C for 10-20s, annealing at 60-70 deg.C and extension for 60-70s, and 40-50 cycles.
9. The method according to claim 8, wherein the step (3) is any one of the following methods: methylation specific quantitative PCR, real-time methylation specific PCR, PCR using methylated DNA specific binding proteins.
10. The kit according to any one of claims 1 to 7 for use in the preparation of a reagent or medical device for early diagnosis, detection or screening of thyroid cancer.
CN202010429151.4A 2020-05-20 2020-05-20 Kit for early diagnosis, detection or screening of thyroid cancer, and use method and application thereof Pending CN111500731A (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
CN202010429151.4A CN111500731A (en) 2020-05-20 2020-05-20 Kit for early diagnosis, detection or screening of thyroid cancer, and use method and application thereof

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
CN202010429151.4A CN111500731A (en) 2020-05-20 2020-05-20 Kit for early diagnosis, detection or screening of thyroid cancer, and use method and application thereof

Publications (1)

Publication Number Publication Date
CN111500731A true CN111500731A (en) 2020-08-07

Family

ID=71873368

Family Applications (1)

Application Number Title Priority Date Filing Date
CN202010429151.4A Pending CN111500731A (en) 2020-05-20 2020-05-20 Kit for early diagnosis, detection or screening of thyroid cancer, and use method and application thereof

Country Status (1)

Country Link
CN (1) CN111500731A (en)

Cited By (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN113699242A (en) * 2021-10-18 2021-11-26 浙江省人民医院 Primer probe, kit and method for detecting KRAS gene mutation, ADAMTS1 and BNC1 methylation
CN113999907A (en) * 2021-11-02 2022-02-01 北京艾克伦医疗科技有限公司 Method and kit for identifying thyroid cancer state
CN114250298A (en) * 2020-09-23 2022-03-29 中国医学科学院北京协和医院 DNA methylation marker of pancreatic ductal adenocarcinoma and application thereof
CN114507734A (en) * 2022-02-11 2022-05-17 博尔诚（北京）科技有限公司 Marker and probe composition for thyroid cancer screening and application of marker and probe composition

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20130288241A1 (en) * 2010-05-25 2013-10-31 The Johns Hopkins University Compositions and methods for detecting a neoplasia
CN108277274A (en) * 2017-01-03 2018-07-13 博尔诚（北京）科技有限公司 Composition and application thereof for differentiating pancreatic cancer and chronic pancreatitis
CN110267744A (en) * 2016-12-12 2019-09-20 塞弗德公司 The purifying and measurement and mutation and/or the common measurement of mRNA expression of the integration of DNA methylation in automation reaction box
CN110387421A (en) * 2019-08-28 2019-10-29 深圳市新合生物医疗科技有限公司 DNA methylation qPCR kit and application method for lung cancer detection

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20130288241A1 (en) * 2010-05-25 2013-10-31 The Johns Hopkins University Compositions and methods for detecting a neoplasia
CN110267744A (en) * 2016-12-12 2019-09-20 塞弗德公司 The purifying and measurement and mutation and/or the common measurement of mRNA expression of the integration of DNA methylation in automation reaction box
CN108277274A (en) * 2017-01-03 2018-07-13 博尔诚（北京）科技有限公司 Composition and application thereof for differentiating pancreatic cancer and chronic pancreatitis
CN110387421A (en) * 2019-08-28 2019-10-29 深圳市新合生物医疗科技有限公司 DNA methylation qPCR kit and application method for lung cancer detection

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
EISSA ET AL.: "Promoter methylation of ADAMTS1 and BNC1 as potential biomarkers for early detection of pancreatic cancer in blood", 《CLINICAL EPIGENETICS》 *

Cited By (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN114250298A (en) * 2020-09-23 2022-03-29 中国医学科学院北京协和医院 DNA methylation marker of pancreatic ductal adenocarcinoma and application thereof
CN113699242A (en) * 2021-10-18 2021-11-26 浙江省人民医院 Primer probe, kit and method for detecting KRAS gene mutation, ADAMTS1 and BNC1 methylation
CN113999907A (en) * 2021-11-02 2022-02-01 北京艾克伦医疗科技有限公司 Method and kit for identifying thyroid cancer state
CN114507734A (en) * 2022-02-11 2022-05-17 博尔诚（北京）科技有限公司 Marker and probe composition for thyroid cancer screening and application of marker and probe composition
CN114507734B (en) * 2022-02-11 2023-08-25 博尔诚（北京）科技有限公司 Marker for thyroid cancer screening, probe composition and application thereof

Similar Documents

Publication Publication Date Title
CN108977543B (en) Colorectal cancer early diagnosis reagent based on joint detection of SDC2 and SFRP2 gene methylation level
CN111500731A (en) Kit for early diagnosis, detection or screening of thyroid cancer, and use method and application thereof
CN110387421A (en) DNA methylation qPCR kit and application method for lung cancer detection
CN109825586B (en) DNA methylation qPCR kit for lung cancer detection and use method
CN111549135A (en) DNA methylation qPCR kit for cervical cancer detection, and use method and application thereof
CN109112216B (en) Triple qPCR (quantitative polymerase chain reaction) detection kit and method for DNA methylation
CN113755603B (en) Marker, primer probe and kit for early screening and diagnosis of endometrial cancer
CN109504780B (en) DNA methylation qPCR kit for lung cancer detection and use method thereof
CN111560435A (en) DNA methylation kit for colorectal cancer detection, and use method and application thereof
CN110964823A (en) DNA methylation kit for colorectal cancer detection and detection method
CN111808962A (en) Kit for cervical cancer detection and use method
CN113652490B (en) Primer probe combination and kit for early screening and/or prognosis monitoring of bladder cancer
CN110592224B (en) Primer group, reagent and kit for methylation of specific region of human colorectal cancer related gene and application of primer group, reagent and kit
CN111826446A (en) Primer, probe and kit for early screening and auxiliary diagnosis of bladder cancer
CN111808963A (en) Composition for noninvasive screening of early lung cancer, application and kit and sample processing method
CN113355414B (en) Esophageal cancer detection kit and application thereof
CN114480655A (en) DNA methylation marker combination and application thereof, ovarian cancer early detection primer probe and kit
CN111793690A (en) DNA methylation qPCR kit for cervical cancer detection and use method thereof
CN113215260A (en) Application of GSTP1, APC and RASSF1 in preparation of prostate cancer markers and kit thereof
CN115961038B (en) Composition for detecting gastric cancer, kit and application thereof
CN111549136A (en) Kit for thyroid cancer detection and using method and application thereof
CN108796078B (en) Primer and probe set for diagnosing, detecting or screening digestive tract cancer
CN112322743A (en) Kit for detecting human SEPT9 gene methylation and use method and application thereof
CN111893183A (en) DNA methylation qPCR kit for cervical cancer detection and use method thereof
CN112391476A (en) Kit for detecting human MLH1 gene methylation and using method thereof

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
WD01 Invention patent application deemed withdrawn after publication
WD01 Invention patent application deemed withdrawn after publication

Application publication date: 20200807